CYP3A4*1B polymorphism and cancer risk: A HuGE review and meta-analysis

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 649-660

  Zhou, Li Ping ^a   Yao, Fan ^a   Luan, Hong ^a   Wang, Yin Ling ^a   Dong, Xi Hua ^a   Zhou, Wen Wen ^a   Wang, Qi Hui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; CYP3A4; Meta analysis; Polymorphism

Indexed keywords

ADENINE; CYTOCHROME P450 3A4; GUANINE; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A;

AFRICAN; ALLELE; ARTICLE; ASIAN; BREAST CANCER; CANCER PATIENT; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; CYP3A4 GENE; DNA POLYMORPHISM; ETHNIC GROUP; ETHNICITY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; HUMAN GENOME; HUMAN TISSUE; LEUKEMIA; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); POPULATION BASED CASE CONTROL STUDY; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RECESSIVE INHERITANCE; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; LITERATURE; META ANALYSIS; NEOPLASM; REVIEW; RISK FACTOR;

CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC; REVIEW LITERATURE AS TOPIC; RISK FACTORS;

MLCS; MLOWN;

EID: 84877110696     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0592-z     Document Type: Article

References (36)

1. Patton GC, Coffey C, Sawyer SM, Viner RM, Haller DM, Bose K, Vos T, Ferguson J, Mathers CD. Global patterns of mortality in young people: a systematic analysis of population health data. Lancet. 2009;374:881-92.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011;61:69-90.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. International journal of cancer Journal international du cancer. 2010;127:2893-917.
4. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62:10-29.
5. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-59.
6. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31:27-36.
7. Loktionov A. Common gene polymorphisms, cancer progression and prognosis. Cancer Lett. 2004;208:1-33.
8. Yang X, Zhang B, Molony C, Chudin E, Hao K, Zhu J, Gaedigk A, Suver C, Zhong H, Leeder JS, Guengerich FP, Strom SC, Schuetz E, Rushmore TH, Ulrich RG, Slatter JG, Schadt EE, Kasarskis A, Lum PY. Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver. Genome Res. 2010;20:1020-36.
9. Wang J. Cyp3a polymorphisms and immunosuppressive drugs in solid-organ transplantation. Expert Rev Mol Diagn. 2009;9:383-90.
10. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H, Drings P, Schulz V, Kayser K, Bartsch H, Risch A. The cyp3a4*1b allele increases risk for small cell lung cancer: effect of gender and smoking dose. Pharmacogenetics. 2003;13:607-18.
11. Sarma AV, Dunn RL, Lange LA, Ray A, Wang Y, Lange EM, Cooney KA. Genetic polymorphisms in cyp17, cyp3a4, cyp19a1, srd5a2, igf-1, and igfbp-3 and prostate cancer risk in African-American men: the flint men's health study. Prostate. 2008;68:296-305.
12. Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes p450 (cyp) as a susceptibility factor for drug response, toxicity, and cancer risk. Arhiv za higijenu rada i toksikologiju. 2009;60:217-42.
13. Nogal A, Coelho A, Catarino R, Morais A, Lobo F, Medeiros R. The cyp3a4*1b polymorphism and prostate cancer susceptibility in a portuguese population. Cancer genetics and cytogenetics. 2007;177:149-52.
14. Voso MT, Fabiani E, D'Alo F, Guidi F, Di Ruscio A, Sica S, Pagano L, Greco M, Hohaus S, Leone G. Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2007;18:1523-8.
15. Ociepa-Zawal M, Rubis B, Filas V, Breborowicz J, Trzeciak WH. Studies on cyp1a1, cyp1b1 and cyp3a4 gene polymorphisms in breast cancer patients. Ginekologia polska. 2009;80:819-23.
16. da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M. Uses and misuses of the strobe statement: Bibliographic study. BMJ open. 2011;1:e000048.
17. Zhang L, Liu JL, Zhang YJ, Wang H. Association between hla-b*27 polymorphisms and ankylosing spondylitis in han populations: a meta-analysis. Clin Exp Rheumatol. 2011;29:285-92.
18. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002;21:1539-58.
19. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genetic epidemiology. 2005;28:123-37.
20. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA: the journal of the American Medical Association. 2006;295:676-80.
21. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM, McCredie MR, Giles GG, Chenevix-Trench G, Liddle C. The cyp3a4*1b polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics. 2002;12:355-66.
22. Yuan XJ, Gu LJ, Zhao HJ, Tang JY, Xue HL, Chen J, Pan C, Chen J, Wang YP. Analysis of cytochrome p450 genotype polymorphism in chinese children with acute leukemia. J Appl Clin Pediatr. 2005;20:654-6.
23. Bangsi D, Zhou J, Sun Y, Patel NP, Darga LL, Heilbrun LK, Powell IJ, Severson RK, Everson RB. Impact of a genetic variant in cyp3a4 on risk and clinical presentation of prostate cancer among white and African-American men. Urol Oncol. 2006;24:21-7.
24. Bolufer P, Collado M, Barragan E, Cervera J, Calasanz MJ, Colomer D, Roman-Gomez J, Sanz MA. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007;92:308-14.
25. Gervasini G, Garcia-Martin E, Ladero JM, Pizarro R, Sastre J, Martinez C, Garcia M, Diaz-Rubio M, Agundez JA. Genetic variability in cyp3a4 and cyp3a5 in primary liver, gastric and colorectal cancer patients. BMC cancer. 2007;7:118.
26. Kato I, Cichon M, Yee CL, Land S, Korczak JF. African American-preponderant single nucleotide polymorphisms (snps) and risk of breast cancer. Cancer epidemiology. 2009;33:24-30.
27. McDaniel DO, Thurber T, Lewis-Traylor A, Berry C, Barber WH, Zhou X, Bigler S, Vance R. Differential association of cytochrome p450 3a4 genotypes with onsets of breast tumors in African American versus caucasian patients. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2011;59:1096-103.
28. Inoue K, Inazawa J, Nakagawa H, Shimada T, Yamazaki H, Guengerich FP, Abe T. Assignment of the human cytochrome p-450 nifedipine oxidase gene (cyp3a4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. The Japanese journal of human genetics. 1992;37:133-8.
29. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human cyp3a-mediated metabolism. Advanced drug delivery reviews. 2002;54:1271-94.
30. Lee SJ, Goldstein JA. Functionally defective or altered cyp3a4 and cyp3a5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics. 2005;6:357-71.
31. Keshava C, McCanlies EC, Weston A. Cyp3a4 polymorphisms-potential risk factors for breast and prostate cancer: a huge review. Am J Epidemiol. 2004;160:825-41.
32. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in cyp3a4. Journal of the National Cancer Institute. 1998;90:1225-9.
33. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA, Casey G, Witte JS. Association between a cyp3a4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 1999;8:901-5.
34. Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M, Gonzalez M, Brunet S, Batlle M, Cervera J, Sanz MA. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol. 2007;136:590-6.
35. Kadlubar FF, Berkowitz GS, Delongchamp RR, Wang C, Green BL, Tang G, Lamba J, Schuetz E, Wolff MS. The cyp3a4*1b variant is related to the onset of puberty, a known risk factor for the development of breast cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2003;12:327-31.
36. Krishna DR, Shekar MS. Cytochrome p450 3a: Genetic polymorphisms and inter-ethnic differences. Methods and findings in experimental and clinical pharmacology. 2005;27:559-67. Department of Liaoning Province